SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-018159
Filing Date
2024-05-08
Accepted
2024-05-08 07:15:59
Documents
62
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 908578
2 ex31-1.htm EX-31.1 26402
3 ex31-2.htm EX-31.2 25772
4 ex32-1.htm EX-32.1 9827
5 ex32-2.htm EX-32.2 9931
  Complete submission text file 0001493152-24-018159.txt   4413786

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cing-20240331.xsd EX-101.SCH 32856
7 XBRL CALCULATION FILE cing-20240331_cal.xml EX-101.CAL 46479
8 XBRL DEFINITION FILE cing-20240331_def.xml EX-101.DEF 130135
9 XBRL LABEL FILE cing-20240331_lab.xml EX-101.LAB 290404
10 XBRL PRESENTATION FILE cing-20240331_pre.xml EX-101.PRE 231759
66 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 635990
Mailing Address 1901 W. 47TH PLACE KANSAS CITY KS 66205
Business Address 1901 W. 47TH PLACE KANSAS CITY KS 66205 (913) 942-2300
Cingulate Inc. (Filer) CIK: 0001862150 (see all company filings)

IRS No.: 863825535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40874 | Film No.: 24924236
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)